Gabather AB (GABA) AI Stock Analysis

• Market Cap: kr17.70M
• Dividend Yield: N/A
• Average Volume (3M): 488.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: N/A
• EPS Growth: 72.30%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 491,634,160
• 10 Day Avg. Volume: 541,248
• 30 Day Avg. Volume: 488,507
• PEG Ratio: 0.02
• Price to Book (P/B): -1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr0.03 ▼(-3.33% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is primarily held down by very weak financial performance (no revenue, recurring losses, negative equity, and ongoing cash burn). Technical indicators provide only modest near-term support, while valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Low Financial Leverage

Having no reported debt materially reduces fixed financing obligations and lowers near-term insolvency risk. For a cash-burning biotech, zero leverage preserves strategic optionality to pursue partnerships or structured financing without debt covenants, supporting survival while R&D advances.

Improving Cash Burn

A marked reduction in cash burn versus 2023 indicates stronger cost discipline and extends operational runway absent new revenue. If sustained, lower negative cash flow reduces immediate financing needs and gives management more time to advance programs or secure non-dilutive partnerships.

Narrowing Net Losses

Progressively smaller net losses reflect improved cost control and operational tightening. Durable reduction in loss magnitude lessens cumulative equity erosion and potential dilution pressure, improving the company's ability to manage development timelines and negotiate collaborations from a stronger position.

Negative Factors

No Revenue

Absence of any revenue means the business lacks commercial validation and has no internal cash generation to fund R&D or ops. Long-term viability hinges on successful product development or external finance, making the company structurally dependent on capital markets or partners to survive.

Negative Shareholders' Equity

Negative equity signals cumulative losses have exhausted capital cushions and impairs solvency metrics. Shrinking asset base reduces collateral and borrowing capacity, increasing leverage for future financing and weakening the company's negotiating position with investors and counterparties over the medium term.

Persistent Negative Cash Generation

Sustained negative operating and free cash flow requires recurring external funding. This ongoing burn elevates dilution and refinancing risk, forces management to prioritize short-term financing over long-term R&D investments, and undermines sustainable growth prospects absent a structural change.

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.

How the Company Makes Money

Gabather AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's business model involves advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval. Success in these trials can lead to partnerships with larger pharmaceutical companies, licensing agreements, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from partnerships, as well as potential sales revenue from successful drug commercialization. Gabather may also engage in research collaborations that contribute to its earnings.

Gabather AB Financial Statement Overview

Summary

Income statement shows no revenue and persistent net losses; cash flow remains negative despite improved burn in 2024; balance sheet risk is elevated due to negative shareholders’ equity and sharply reduced assets, even though reported debt is zero.

Income Statement

The company reports no revenue across the period provided, while losses are persistent every year (net loss of ~SEK 7.8m in 2024 vs ~SEK 9.4m in 2023, and materially larger losses in earlier years). The main positive is that losses have narrowed from the 2020–2021 peak, suggesting some cost control, but profitability remains deeply negative with no visible top-line traction in the data.

Balance Sheet

Reported debt is zero, which reduces financial-risk from leverage. However, the balance sheet has weakened substantially: shareholders’ equity fell from positive levels in prior years to negative in 2024 (about -SEK 4.2m), indicating accumulated losses have overtaken the capital base. Total assets have also contracted sharply over time (from ~SEK 46.1m in 2019 to ~SEK 1.8m in 2024), which limits financial flexibility.

Cash Flow

Cash generation is consistently negative, with operating and free cash flow both at about -SEK 3.3m in 2024, following much heavier cash burn in 2023 (-SEK 11.6m). The improvement in 2024 is a near-term positive, but free cash flow growth is still negative year over year and the business remains reliant on external funding to sustain operations given ongoing cash outflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-4.12M	0.00	37.00K	-8.55M	-16.99M	-14.66M
Net Income	-4.46M	-7.75M	-9.44M	-8.54M	-17.00M	-14.95M
Balance Sheet
Total Assets	3.50M	1.83M	7.36M	6.75M	15.39M	32.16M
Cash, Cash Equivalents and Short-Term Investments	3.00M	878.00K	1.11M	6.27M	14.85M	30.92M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.48M	6.01M	6.88M	3.31M	4.43M	3.31M
Stockholders Equity	-983.00K	-4.17M	486.00K	3.44M	10.96M	27.91M
Cash Flow
Free Cash Flow	-5.16M	-3.33M	-11.64M	-9.60M	-16.12M	-13.98M
Operating Cash Flow	-5.16M	-3.33M	-11.64M	-9.60M	-16.12M	-13.69M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	-289.00K
Financing Cash Flow	7.18M	3.09M	6.49M	1.02M	46.00K	0.00

Gabather AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.55 is Neutral, neither overbought nor oversold. The STOCH value of 59.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GABA.

Gabather AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NANEXA	56 Neutral	kr632.32M	-54.51	-48.65%	―	-60.33%	58.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALZCUR	44 Neutral	kr216.61M	-4.11	-90.66%	―	―	15.74%
ERMA	44 Neutral	kr56.84M	-0.64	―	―	―	―
VIVE	43 Neutral	kr89.68M	-1.47	-24.23%	―	―	―
GABA	42 Neutral	kr17.70M	-0.95	―	―	―	72.30%
KLAR	42 Neutral	kr201.21M	-3.66	-530.21%	―	―	17.42%